Tenemine 300 mg, 200 mg FC tablet
PDF Leaflet Revision Date: 05 November 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection and pre-exposure prophylaxis (PrEP) in high-risk adults.
Dosage (summary)
One tablet daily, with or without food.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; avoid breastfeeding due to potential HIV transmission.
Key Drug Interactions
- Avoid with other tenofovir or emtricitabine containing medicines
- Caution with nephrotoxic drugs
Contraindications
- Hypersensitivity to components
- Creatinine CL < 60 mL/min for PrEP
- Creatinine CL < 50 mL/min for treatment
Common side effects
- Neutropenia
- Dizziness
- Diarrhea
- Nausea
- Rash
Counselling Points
- Adhere strictly to dosing schedule
- Use additional preventive measures for HIV
- Monitor for signs of lactic acidosis
Serious warnings
- Lactic acidosis
- Severe hepatotoxicity
- Risk of HIV transmission persists
Important Disclaimer
The Tenemine 300 mg, 200 mg FC tablet professional information leaflet below is the property of Viatris Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
